See more : Bookoff Group Holdings Limited (9278.T) Income Statement Analysis – Financial Results
Complete financial analysis of ZIOPHARM Oncology, Inc. (ZIOP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZIOPHARM Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Great Wall Motor Company Limited (GWLLF) Income Statement Analysis – Financial Results
- Formuepleje Mix High (FPIMHI.CO) Income Statement Analysis – Financial Results
- AVVAA World Health Care Products, Inc. (AVVH) Income Statement Analysis – Financial Results
- HighGold Mining Inc. (HIGH.V) Income Statement Analysis – Financial Results
- Restaurant Brands New Zealand Limited (RTBRF) Income Statement Analysis – Financial Results
ZIOPHARM Oncology, Inc. (ZIOP)
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 52.70M | 38.33M | 34.13M | 45.08M | 157.79M | 106.79M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 120.00 |
| SG&A | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 120.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 486.00 | -42.51K | 74.14K |
| Operating Expenses | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | -42.51K | 74.26K |
| Cost & Expenses | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.13M | 629.00K | 575.00K | 369.00K | 290.00K | 357.00K | 462.00K | 738.00K | 658.00K | 268.00K | 188.00K | 330.00K | 388.00K | 433.35K | 173.92K | 101.23K | 0.00 | 486.00 | 799.00 | 750.00 |
| EBITDA | -78.85M | -117.17M | -52.54M | -53.95M | -165.01M | -119.73M | -31.32M | -56.37M | -95.47M | -63.51M | -32.48M | -7.32M | -24.84M | -26.17M | -17.68M | -9.42M | -39.17K | -35.36K | -39.14K | -71.79K |
| EBITDA Ratio | 0.00% | 0.00% | -35,987.67% | -844.48% | -2,405.00% | -2,763.87% | -2,281.06% | -7,046.13% | -11,934.25% | -9,521.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,523.04% | -4,159.04% |
| Operating Income | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Operating Income Ratio | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.62M | -8.12M | 4.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -56.16M | -40.79M | -3.18M | 0.00 | 0.00 | 0.00 | 0.00 | -39.17K | -35.84K | -39.94K | -72.54K |
| Income Before Tax Ratio | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -8,419.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.62M | -8.12M | 4.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Net Income Ratio | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| EPS | -0.38 | -0.70 | -0.37 | -0.40 | -1.27 | -0.96 | -0.31 | -0.66 | -1.22 | -0.97 | -0.71 | -0.33 | -1.19 | -1.41 | -1.42 | -2.32 | -0.29 | -0.31 | -0.36 | -0.80 |
| EPS Diluted | -0.38 | -0.70 | -0.37 | -0.40 | -1.27 | -0.96 | -0.31 | -0.66 | -1.22 | -0.97 | -0.71 | -0.33 | -1.19 | -1.41 | -1.42 | -2.32 | -0.29 | -0.31 | -0.36 | -0.80 |
| Weighted Avg Shares Out | 209.64M | 167.95M | 143.71M | 136.94M | 130.39M | 125.42M | 101.13M | 85.94M | 78.55M | 66.00M | 46.00M | 23.11M | 21.23M | 18.83M | 12.57M | 4.10M | 135.99K | 116.82K | 112.49K | 90.27K |
| Weighted Avg Shares Out (Dil) | 209.64M | 167.95M | 143.71M | 136.94M | 130.39M | 125.42M | 101.13M | 85.94M | 78.55M | 66.00M | 46.00M | 23.11M | 21.23M | 18.83M | 12.57M | 4.10M | 135.99K | 116.82K | 112.49K | 90.27K |
WaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm Oncology
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting
Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer
Ziopharm Oncology Appoints Mary Thistle to Board of Directors
Ziopharm Oncology to Participate in Jefferies Virtual London Healthcare Conference on November 19, 2020
ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q3 2020 Results - Earnings Call Transcript
WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders
Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
Source: https://incomestatements.info
Category: Stock Reports